Related Experiment Videos
Rectal cancer adjuvant therapy controversies: When? What? Why?
1Division of Colon and Rectal Surgery, Department of Surgery, Jefferson Medical College, Philadelphia, Pennsylvania, USA.
Surgical Oncology Clinics of North America
|September 29, 2000
Summary
Adjuvant therapy for high-risk rectal cancer is recommended, but optimal timing, methods, and agents remain debated. This review covers current practices, scientific evidence, and emerging treatments for rectal cancer management.
Area of Science:
- Oncology
- Surgical Oncology
- Medical Oncology
Background:
- Adjuvant therapy is crucial for high-risk rectal cancer.
- Current treatment protocols face ongoing debates regarding optimal application.
Purpose of the Study:
- To review current adjuvant therapy practices for high-risk rectal cancer.
- To discuss the scientific basis and evidence supporting these practices.
- To explore novel therapeutic strategies and drug delivery methods.
Main Methods:
- Literature review of existing studies on rectal cancer adjuvant therapy.
- Analysis of current clinical practice guidelines and recommendations.
- Evaluation of evidence for induction therapy and new anticancer agents.
Main Results:
- Established practices for adjuvant therapy in rectal cancer are presented.
- Scientific rationale and supporting data for current recommendations are discussed.
- Emerging evidence on novel agents and drug delivery systems is highlighted.
Conclusions:
- While adjuvant therapy is standard, optimization of timing, mode, and agents is needed.
- Further research into induction therapy and new agents is warranted for improved rectal cancer outcomes.